C12Y 304/21022
Coagulation factor ixa
Official title: Coagulation factor IXa (3.4.21.22)
C12Y304/21022 (Coagulation factor ixa) appears on 414 US grants and 646 published applications in this corpus.
Search patents in C12Y- Granted patents
- 414
- Published applications
- 646
- Assignees
- 216
- Inventors
- 699
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 3 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 8 | 0 |
| 1999 | 10 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 1 |
| 2002 | 4 | 8 |
| 2003 | 8 | 11 |
| 2004 | 4 | 15 |
| 2005 | 2 | 9 |
| 2006 | 3 | 9 |
| 2007 | 8 | 8 |
| 2008 | 9 | 24 |
| 2009 | 4 | 11 |
| 2010 | 12 | 23 |
| 2011 | 11 | 23 |
| 2012 | 7 | 23 |
| 2013 | 7 | 23 |
| 2014 | 15 | 51 |
| 2015 | 21 | 29 |
| 2016 | 22 | 51 |
| 2017 | 32 | 44 |
| 2018 | 17 | 46 |
| 2019 | 31 | 49 |
| 2020 | 31 | 39 |
| 2021 | 29 | 52 |
| 2022 | 17 | 29 |
| 2023 | 15 | 19 |
| 2024 | 9 | 15 |
| 2025 | 13 | 21 |
| 2026 | 7 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inter-application workflow performance analytics18 Aug 2026US 12,711,443 B2Box, Inc.
- Factor IX polypeptide formulations16 Jun 2026US 12,653,871 B2Bioverativ Therapeutics Inc.
- Isolated modified VP1 capsid protein of AAV59 Jun 2026US 12,649,766 B2
- Hemophilia B rat model2 Jun 2026US 12,642,256 B2Toolgen Incorporated
- Medicinal composition usable for preventing and/or treating blood coagulation factor IX abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor VIII14 Apr 2026US 12,600,798 B2Chugai Seiyaku Kabushiki Kaisha
- Engineered cell preparations for treatment of hemophilia24 Sep 2026US 2026/0286298 A1Be Biopharma, Inc.
- Nucleic acid constructs and methods of use17 Sep 2026US 2026/0273105 A1Intellia Therapeutics, Inc.
- Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof3 Sep 2026US 2026/0258443 A1Kanglin Biotech (Hangzhou) Co., Ltd.
- Treatment of hemophilia a with fitusiran2 Jul 2026US 2026/0185097 A1Genzyme Corporation
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
Most cited
By later US patents
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008
- Expression of factor VII activity in mammalian cells201US 4,784,950 AZymoGenetics, Inc. · 1988